Navigation Links
New research may overturn conventional wisdom on drug-resistant tuberculosis

A newly released study suggests that the majority of cases of drug-resistant tuberculosis (TB) among patients undergoing treatment for the disease may be due to new infections, not acquired resistance. If confirmed in future studies the research, in the March 15 issue of The Journal of Infectious Diseases, may drive a major shift in strategy for controlling TB.

A major difficulty in treating patients with pulmonary TB is that the organism can become progressively resistant to standard therapy. This resistance was long thought to be acquired through mutations in the infecting strain when the treatment regimen was inadequate or the patient did not comply with it. More recently, studies of the genetic make-up of Mycobacterium tuberculosis (M. tuberculosis) strains have shown that resistance can also result from re-infection with a new strain that is already drug-resistant, sometimes against multiple drugs.

The authors of the new study, Qian Gao, PhD, and coworkers in Shanghai, China and elsewhere, used molecular genetics and drug susceptibility testing to investigate patients with TB who were treated in Shanghai hospitals during 1999-2004. They focused on 38 patients from whom samples were available before and during treatment. The researchers found that the strains of TB in the samples taken before treatment were genetically different from those taken during treatment in 87 percent (33 out of 38) of patients.

To determine the relative proportion of drug resistance caused by re-infection or mutation, the authors excluded six patients who were initially infected with resistant TB and then became drug-susceptible or resistant to fewer drugs. In the remaining 32 patients, the initial sample was drug-susceptible or resistant to at least one drug and the subsequent sample resistant to one or more drugs. Of these patients, 84 percent (27 patients) had before-and-during samples with different genetic patterns and only 16 percent (5 patients) had id
'"/>

Source:Infectious Diseases Society of America


Page: 1 2 3

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Feb. 1, 2008) This months issue of ... methods to understand developmental processes in plants and flies. ... on the Web site for Cold Spring Harbor Protocols ... use of RNAi to investigate gene function in fruit flies. ...
... the role of a gene important to the embryonic ... coordination of differentiation of immature neural cells with the ... now, the mechanisms regulating these distinct cellular activities have ... published in the Feb. 15 issue of Development. ...
... Scientists at the University of Alabama at Birmingham ... uncover new details about the infectious potency of poxviruses, ... infections can subvert the bodys immune system. Having ... the discovery of new drugs to combat inflammation and ...
Cached Biology News:RNA-based methods for developmental studies are featured in Cold Spring Harbor Protocols 2Trainor Lab characterizes gene essential for prenatal development of nervous system 2Poxvirus potency uncovered in new atomic map 2
(Date:6/1/2015)... , June 1, 2015 ... that it will be participating in the Jefferies 2015 ... on Tuesday, June 2, 2015. Jeff ... question and answer session at 10:00 a.m. ET (3:00 ... be available on the Presentations and Webcasts section of ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Assessments of Leading Microbiology ... Recent Market Entrants" report to their ... from VPGMarketResearch.com provides insightful profiles of leading ... The report presents strategic assessments, ...
(Date:5/31/2015)... BARCELONA, Spain , June 1, 2015 /PRNewswire/ ... company dedicated to rare diseases, has selected Veeva ... across sales, marketing, and medical. A complete solution, ... data, multichannel interactions, and compliant content to provide ... and effective commercial execution.      (Logo: ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The ... novel research for bile duct cancer, announced today ... Research Fellowship Program. , The Foundation ... scientists throughout the country to raise awareness about ... will support research that opens new pathways for ...
Breaking Biology Technology:Assessments of Leading Microbiology Market Players 2015 - Profiles of Major Suppliers and Recent Market Entrants 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3
... year,s first , quarter , - Total revenue of ... million , - Earnings per share of $0.29, an increase of ... - New products launched containing life,sDHA(TM) in a variety of , ... demonstrate the strong , leverage in our businessCOLUMBIA, Md., ...
... MOUNTAIN VIEW, Calif., March 4 The Healthcare ... pleased to announce its 2009 Quarterly Analyst Briefing ... be held on Thursday, March 5, 2009 at ... industry has witnessed healthy growth and is experiencing ...
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... fourth quarter of 2008 was $334,041 compared to $174,071 for ... from the sale of PCT products and services was $233,256 ... $118,703 for the same period in 2007, a 97% increase. ...
Cached Biology Technology:Martek Announces First Quarter 2009 Financial Results 2Martek Announces First Quarter 2009 Financial Results 3Martek Announces First Quarter 2009 Financial Results 4Martek Announces First Quarter 2009 Financial Results 5Martek Announces First Quarter 2009 Financial Results 6Martek Announces First Quarter 2009 Financial Results 7Martek Announces First Quarter 2009 Financial Results 8Martek Announces First Quarter 2009 Financial Results 9Martek Announces First Quarter 2009 Financial Results 10Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 3Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 4Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 5Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 6Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 7Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 8
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: